Toshihiko Mizuta

Dr. Toshihiko Mizuta


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JXjinghe xia
jinghe xia
IOIwata Ozaki
Iwata Ozaki
SMSachiko Matsuhashi
Sachiko Matsuhashi
TKTakuya Kuwashiro
Takuya Kuwashiro
Hirokazu TakahashiHirokazu Takahashi
Hirokazu Takahashi
TMToshihiko Mizuta
Toshihiko Mizuta
Hypoxia-inducible factor 1 (HIF-1) plays important roles in cancer cell biology. HIF-1α is reportedly activated by several factors, including protein kinase C (PKC), in addition to hypoxia. We investigated the role of PKC isoforms and the effects of vitamin K2 (VK2) in the activation process of HIF-1α. Human hepatocellular carcinoma (HCC)-derived Huh7 cells were cultured under normoxic and hypoxic (1% O2) conditions with or without the PKC stimulator TPA. The expression, transcriptional activity and nuclear translocation of HIF-1α were examined under treatment with PKC inhibitors, siRNAs against each PKC isoform and VK2. Hypoxia increased the expression and activity of HIF-1α. TPA increased the HIF-1α activity several times under both normoxic and hypoxic conditions. PKC-δ siRNA-mediated knockdown, PKC-δ inhibitor (rottlerin) and pan-PKC inhibitor (Ro-31-8425) suppressed the expression and transcriptional activity of HIF-1α. VK2 significantly inhibited the TPA-induced HIF-1α transcriptional activity and suppressed the expression and nuclear translocation of HIF-1α induced by TPA without altering the HIF-1α mRNA levels. These data indicate that PKC-δ enhances the HIF-1α transcriptional activity by increasing the nuclear translocation, and that VK2 might suppress the HIF-1α activation through the inhibition of PKC in HCC cells.

3 January 2022 in BMC Cancer
Verified
Journal Article
Open access
PDF file
TSTaro Shibuki
Taro Shibuki
TMToshihiko Mizuta
Toshihiko Mizuta
MSMototsugu Shimokawa
Mototsugu Shimokawa
FKFuta Koga
Futa Koga
YUYujiro Ueda
Yujiro Ueda
TOTaiga Otsuka
Taiga Otsuka
Background: No reliable nomogram has been developed until date for predicting the survival in patients with unresectable pancreatic cancer undergoing treatment with gemcitabine plus nab–paclitaxel (GnP) or FOLFIRINOX. Methods: This analysis was conducted using clinical data of Japanese patients with unresectable pancreatic cancer undergoing GnP or FOLFIRINOX treatment obtained from a multicenter study (NAPOLEON study). A Cox proportional hazards model was used to identify the independent prognostic factors. A nomogram to predict 6–, 12–, and 18–month survival probabilities was generated, validated by using the concordance index (C–index), and calibrated by the bootstrapping method. And then, we attempted risk stratification for survival by classifying the patients according to the sum of the scores on the nomogram (total nomogram points). Results: A total of 318 patients were enrolled. A prognostic nomogram was generated using data on the Eastern Cooperative Oncology Group performance status, liver metastasis, serum LDH, serum CRP, and serum CA19–9. The C–indexes of the nomogram were 0.77, 0.72 and 0.70 for 6–, 12–, and 18–month survival, respectively. The calibration plot showed optimal agreement at all points. Risk stratification based on tertiles of the total nomogram points yielded clear separations of the survival curves. The median survival times in the low–, moderate–, and high–risk groups were 15.8, 12.8 and 7.8 months (P<0.05), respectively. Conclusions: Our nomogram might be a convenient and inexpensive tool to accurately predict survival in Japanese patients with unresectable pancreatic cancer undergoing treatment with GnP or FOLFIRINOX, and will help clinicians in selecting appropriate therapeutic strategies for individualized management.

20 August 2017 in Medical Science Monitor
Verified
Journal Article
Closed access
PDF file
TSTaro Shibuki
Taro Shibuki
TOTaiga Otsuka
Taiga Otsuka
HIHiroshi Isoda
Hiroshi Isoda
NANorimasa Araki
Norimasa Araki
YKYoshihito Kubotsu
Yoshihito Kubotsu
S(Saga Study Group of Liver Diseases (SASLD)
Saga Study Group of Liver Diseases (SASLD)
BACKGROUND:It is important to avoid relapse in autoimmune hepatitis (AIH) because repeated multiple relapses have been associated with a worse prognosis. However, risk factors for relapse before initiation of treatment are not fully understood. The a...

15 May 2015 in Diseases
Verified
Journal Article
Open access
PDF file
TOTaiga Otsuka
Taiga Otsuka
SNShunya Nakashita
Shunya Nakashita
KYKimihiko Yanagita
Kimihiko Yanagita
KAKeisuke Ario
Keisuke Ario
HKHiroaki Kawasoe
Hiroaki Kawasoe
TMToshihiko Mizuta
Toshihiko Mizuta
Sorafenib exerts modest antitumor activity in patients with advanced hepatocellular carcinoma (HCC), and radiological progressive disease (rPD) does not always correspond to so-called clinical progressive disease (cPD). We evaluated 101 patients who initiated sorafenib treatment for HCC and assessed post-progression survival (PPS) using the Cox proportional hazards model. PPS was calculated from the date of the first rPD until the date of death or the last follow-up. Using Cox model analysis of the 76 patients who experienced first rPD, we identified the Child-Pugh class, Eastern Cooperative Oncology Group performance status, the best antitumor response during treatment (using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1) and α-fetoprotein levels as independent factors affecting PPS. When these factors were used to define scores ranging from zero to five with a cutoff value of two, PPS of patients who received best supportive care (BSC) after rPD was not statistically significantly different from that of patients who received post-rPD therapy with scores ≥2 (p = 0.220). In contrast, the PPS for the post-rPD therapy group was significantly longer compared with the BSC patients with scores <2 (p < 0.001). Patients who scored ≥2 at their first rPD were judged cPD and as candidates for BSC.

1 January 2017 in Internal Medicine
Verified
Journal Article
Open access
TSTaro Shibuki
Taro Shibuki
HKHiroharu Kawakubo
Hiroharu Kawakubo
KKKojiro Kawachi
Kojiro Kawachi
TMToshihiko Mizuta
Toshihiko Mizuta

1 January 2017 in Internal Medicine
Verified
Journal Article
Open access
PDF file
TSTaro Shibuki
Taro Shibuki
HGHirofumi Goto
Hirofumi Goto
KFKosuke Fukushima
Kosuke Fukushima
TMToshihiko Mizuta
Toshihiko Mizuta